Princeton, NJ – April 10th, 2025 – KYBORA, a global healthcare advisory firm and investment bank, is proud to announce that Erik Heinnickel, has joined the company as Senior Director Operations. With nearly two decades of experience in analytics and operational leadership across pharmaceuticals, biotech, and other industries, Erik brings a data-driven, collaborative approach to building […]
Trends, Insights, and Strategic Implications The first quarter of 2025 marked a dynamic start to the year for the biopharma sector, continuing momentum from 2024’s wave of transformative transactions. Mergers and acquisitions (M&A), strategic licensing agreements, and novel collaborations were driven by three core themes: expansion in oncology, growing investment in immunology and neurology, and […]
Key Trends and Insights Global Out-Licensing and Partnerships In 2024, the biopharma sector saw a remarkable resurgence in activity, driven by global licensing and partnerships. The U.S. led the market with $7.0 billion across 373 deals, followed by the EMEA with $3.9 billion in 167 deals and the APAC region with $3.0 billion in 133 […]
Transforming Medicine Oligonucleotide-based therapeutics are rapidly emerging as a transformative class of drugs, capable of targeting previously untreatable diseases at their genetic roots. These molecules, encompassing antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and mRNA-based therapies, work by modulating gene expression with unparalleled precision. The global antisense oligonucleotide (ASO) drug market has experienced significant growth, […]
Transforming Precision Medicine with Targeted Therapies Radiopharmaceuticals are transforming precision medicine by offering targeted diagnostic and therapeutic solutions. These innovative treatments focus radiation on diseased tissues, minimizing damage to healthy cells. With significant advancements in diagnostics, theranostics, and radionuclide therapies, radiopharmaceuticals are transforming oncology, cardiology, and neurology. Despite challenges like isotope supply constraints and infrastructure […]
Episode 1: The Science and Business Behind Healthcare In the first episode of our podcast, host Alan Vanderborght, CEO of KYBORA, welcomes guest John Gregg, Chairman and CEO at BalinBac Therapeutics, for an engaging conversation about his extensive experience in the industry. They discuss the evolution of Healthcare, groundbreaking scientific innovations and the trends shaping […]
Diane’s story is a powerful testament to human potential and resilience As the eldest of three children, Diane’s journey began with a dream and a leap of faith. With the support of Foundation Rwanda, she graduated from secondary school and pursued a vocational course in hairdressing. Backed by a microloan from our KYBORA entrepreneurial program, […]
The intersection of artificial intelligence (AI) and protein biology marks the dawn of a transformative era in therapeutic development. Historically, the complexity of protein folding and design posed significant challenges, constrained by the limits of empirical methodologies. Recent breakthroughs, led by innovations such as DeepMind’s AlphaFold, have redefined our understanding of protein structure prediction. This […]
This document offers an in-depth analysis of molecular drug targets in key therapeutic areas, including oncology, immunology, neuroscience, and rare diseases. It highlights emerging trends such as the rise of personalized medicine, RNA-based therapeutics, disease-modifying strategies, and innovative technologies like gene therapies and platform-based discovery approaches.By examining both established and investigational agents, the analysis reveals […]
Spotlight on CAR-T, TIL, and TCR Therapies Cellular immunotherapies, including CAR-T, TIL, and TCR therapies, have transformed modern medicine, offering personalized approaches to treat cancer and autoimmune diseases. CAR-T therapy has demonstrated exceptional efficacy in hematologic malignancies, though challenges such as side effects, manufacturing complexity, and limited solid tumor applicability persist. Emerging in vivo CAR-T […]
